G
aucher disease (GD) is a lysosomal storage disorder that results from insufficient clearance of cellular glucosylceramide, the substrate for the lysosomal enzyme, acid ␤-glucosidase (EC 3.2.1.45; glucocerebrosidase). The pathologic accumulations of glucosylceramide in lysosomes of tissue macrophages results in splenomegaly, hepatomegaly, anemia, thrombocytopenia, and multiple forms of skeletal pathology. [1] [2] [3] [4] [5] In the Western world, GD type 1 (GD1) is the most prevalent variant (94%) and is classically differentiated from types 2 (1%) and 3 (5%) by the absence of primary central nervous system involvement. 1, 6 GD1 is an ultraorphan disease, with an estimated worldwide prevalence of 1 in 60,000. 7 The current standard of care for the treatment of GD1 is enzyme replacement (or more appropriately, reconstitution) therapy with imiglucerase, a recombinant form of glucocerebrosidase. Alglucerase, derived from placental tissue, was used before the availability of imiglucerase. A randomized clinical trial comparing alglucerase and imiglucerase found these enzymes to be therapeutically equivalent in safety and efficacy. 8 Whether enzyme therapy has dose-dependent treatment effects has been a subject of debate since the first clinical trial of alglucerase was published in 1991. 9 In 1995, a panel convened by the National Institutes of Health highlighted the importance of determining whether enzyme therapy has dose-dependent treatment effects. 10 Dosing practices for enzyme therapy have varied around the world because, in part, of the lack of clear evidence of doseresponse relationships. 9, [11] [12] [13] [14] [15] For patients with bone disease or other severe manifestations of GD, the recommendation has been to use higher doses. 16, 17 Given the high cost of therapy and the great phenotypic heterogeneity between patients with GD1, the goal of treatment has been to identify individualized dosing regimens that can achieve optimal long-term outcomes for each patient. 18 Ideally, dose-response relationships would be evaluated by conducting a randomized clinical trial with multiple arms. For rare diseases, such as GD1, this study design would not be practical or feasible because of the large number of subjects and length of follow-up needed to achieve adequate statistical power. As an alternative, analyses of observational data from a large international disease registry using standard epidemiologic matching and modeling methods may offer a feasible and methodologically sound approach.
In the present analyses, data from the International Collaborative Gaucher Group (ICGG) Gaucher Registry were analyzed using propensity scoring methods to match patients between dosing groups 19 -22 to approximate conditions under a randomized trial. Nonlinear mixed effects modeling of these matched data sets was used to assess dose-response relationships across disease parameters.
MATERIALS AND METHODS

ICGG Gaucher registry
The ICGG Gaucher Registry was established in 1991 to track the clinical, biochemical, and therapeutic response characteristics of patients with GD, irrespective of disease severity and treatment status. 6 The main objectives of the Registry are to define the characteristics of GD and assess the long-term outcomes of treatment. The Registry receives scientific direction from an independent international group of physician experts in GD, and operational and financial support from Genzyme Corporation (Cambridge, MA). With appropriate Institutional Review Board/Ethics Committee approvals, over 700 physicians from 60 countries have voluntarily submitted anonymized patient data to the Registry since 1991.
Study population
As of August 4, 2006 , 4434 patients with GD were enrolled in the ICGG Gaucher Registry. The dataset for the present analyses included all GD1 patients enrolled who had been diagnosed after January 1, 1991 (the inception of the Registry), had received enzyme therapy with either alglucerase (Ceredase®, Genzyme Corporation, Cambridge, MA) or imiglucerase (Cerezyme, Genzyme Corporation, Cambridge, MA), and who had not had a partial or total splenectomy (n ϭ 1238). In the present study, 95.6% of patients received imiglucerase, whereas 4.4% only received alglucerase. For the purposes of this analysis, enzyme therapy refers to alglucerase and/or imiglucerase treatment.
The diagnosis of GD1 was based on clinical parameters and the defective activity of acid ␤-glucosidase activity in peripheral blood leukocytes or cultured skin fibroblasts, and/or genotyping of the glucocerebrosidase gene. Included patients had at least one recorded observation at baseline (around the time of first infusion of enzyme therapy) among the following hematological and visceral parameters: hemoglobin concentration, platelet count, and hepatic or splenic volume (n ϭ 948). The following date ranges at baseline were referenced: hemoglobin concentration and platelet counts from 6 months before through 0.5 months after first imiglucerase/ alglucerase infusion; hepatic and splenic volumes from 12 months before through 6 months after first infusion of enzyme therapy. The final group of patients eligible for propensity score matching was the subset who had all four hematological and visceral parameters recorded on or after the first infusion of enzyme therapy (n ϭ 586). Importantly, this patient dataset and the final matched patient dataset (n ϭ 366) had disease parameter characteristics that were representative of the entire patient dataset across all parameters from the original dataset of patients (n ϭ 1238) (see Table, Supplemental Digital Content 1, http://links.lww.com/A694).
Dose of Enzyme Replacement Therapy
Enzyme therapy dosing data are typically recorded in the Registry at the time of first infusion, at any dose change, and periodically if no change was made. Because the ICGG Gaucher Registry does not require adherence to specific dosing protocols, physicians can adjust dose levels up or down at their discretion after initiation of therapy. To account for this variation, the average dose of enzyme therapy across the initial 3 years of therapy was calculated for each patient and then categorized into three groups: Group A (5 to Ͻ29 U/kg/2 weeks), Group B (29 to Ͻ48 U/kg/2 weeks), and Group C (48 to Ͻ75 U/kg/2 weeks). When the number of years after initiation of therapy as the basis for calculating average dose of enzyme therapy was varied, the results were consistent (see Table, Supplemental Digital content 2, http://links.lww.com/A695). The age distributions within each dosing group are in Table, Supplemental Digital Content 3, http://links.lww.com/A696.
Outcomes
The study outcomes were changes in hemoglobin concentration, platelet count, and hepatic and splenic volumes (multiples of normal). These were selected as the parameters most frequently analyzed in previous clinical trials and the parameters with the most data available in the ICGG Gaucher Registry. Hemoglobin was normalized and analyzed as the actual values minus the lower limit of normal for age and sex, as follows: Ͻ6 months, Ͻ10.1 (g/dL); 6 months-2 years, Ͻ9.5 (g/dL); Ͼ2-12 years, Ͻ10.5 (g/dL); male Ͼ12 years, Ͻ12 (g/dL); and female Ͼ12 years, Ͻ11 (g/dL). Hepatic and splenic volumes were determined by magnetic resonance imaging, computed tomography, or ultrasonography and reported as multiples of normal. Ultrasound measurements were converted to volumetric equivalents using the formula previously developed. 23 
Propensity score matching
To limit potential confounding by indication (e.g., greater disease severity in the higher dosing groups), the propensity score matching method was used to identify comparable groups of patients across relevant variables associated with initiation of enzyme therapy. 20 The propensity score, calculated through a logistic regression model, represented the probability of being in the Group C dose group relative to the other two combined groups (Groups A and B). The following variables were included in the logistic regression model: age at diagnosis, age at first infusion, values of hemoglobin and platelet levels, and hepatic and splenic volumes at the time of first infusion of enzyme therapy. Not all patients had measurements for hemoglobin, platelet, hepatic volume, and splenic volume recorded in the Registry precisely at the time of first infusion. Therefore, nonlinear mixed effects models were used to impute values of these variables at the time of first infusion. The consistency of the distribution of baseline disease parameters in the final analysis population (n ϭ 366) with the entire patient datasets (either n ϭ 586 or n ϭ 1238) provided confidence in the imputed values (Tables 1, Supplemental Digital Content 1, http://links.lww.com/A694). Patients from the Groups A and B were individually matched to members of Group C within a range of 0.025 of the propensity score.
Dose-response analysis
To analyze the effect of dose, nonlinear mixed effects models using the maximal effect of dose (E max ) parameterization 24 were constructed for each of the four study outcomes. This parameterization permitted estimation of the E max along with the time required to achieve 50% of the maximal effect (T 50 ). This T 50 value differs significantly in meaning from two more familiar such values: (1) A T 1/2 has been used in many enzyme therapy studies to represent the time to a 50% change in outcome parameter, e.g., time to a 50% reduction in splenic volume and (2) the t 1/2 as the typical pharmacokinetic disappearance half-life of imiglucerase/alglucerase in plasma/serum. Because the distributions of platelet count, splenic volume, and hepatic volume were skewed, these parameters were log transformed for the purpose of model construction. Therefore, the E max is interpreted as a relative change from the time of first infusion for these outcomes. Results from the models are depicted in both graphical and tabular formats. Nonparametric Loess curves of the outcomes were evaluated to confirm that the E max parameterization was the appropriate form of the nonlinear mixed model. Sensitivity analyses were conducted for the matched (n ϭ 366) and unmatched (n ϭ 586) datasets to estimate the robustness of the final model by including terms for the propensity score main, along with interactions between the propensity score and E max and T 50 parameters. All analyses were conducted in SAS 8.2 (SAS Institute Inc., Cary, NC).
RESULTS
Patient characteristics are shown before (n ϭ 586) and after propensity score matching in Table 1 (n ϭ 366; 122 patients in each of three dosing groups). Before matching, the three groups differed significantly across several parameters: age at diagnosis (P ϭ 0.02), age at baseline (P Ͻ 0.01), platelet count (P ϭ 0.02), and hepatic volume (P ϭ 0.04). After matching, there were no statistically significant differences between the three dosing groups (Table 1) . These matched sets were used for all final analyses. Dose-response relationships were found for each parameter: hemoglobin concentration, platelet count, splenic volume, and hepatic volume. For all four parameters, Group C achieved highest maximal treatment effects.
For hemoglobin concentration, the model results are shown in Figure 1 , A and B. For Group A, the E max for hemoglobin was an increase of 1.45 g/dL above baseline and the T 50 was 3.76 months. For Group B, the E max was an increase of 1.74 g/dL from baseline and T 50 was 4.21 months. The E max and T 50 values for Group C were 2.32 g/dL and 5.28 months, respectively. Furthermore, the plateaus in responses out to 96 months were maintained with stratification by the three dosing groups.
For platelet counts (Fig. 2, A and B) , Group A showed E max and T 50 of 1.97-fold increase from baseline and 18.09 months, respectively. In comparison, Groups B and C differed from the lowest dose group, with the Group C having the greatest response with E max of 2.1-fold increase from baseline and T 50 ϭ 4.83 months. The curves seem to be converging beyond 96 months of ERT to a level of ϳ2.2 to 2.3-fold increase above baseline in all three groups. However, the rates of response to dose clearly segregate between 0 and 60 months of enzyme therapy. A greater response rate was evident in Group C compared with either Groups A or B.
Splenic volume dose-response relationships are shown in Figure 3 , A and B. The E max values were 0.32, 0.22, and 0.10 from baseline for Groups A, B, and C, respectively, correspond- ing to reductions of 68%, 78%, and 90% in splenic volumes from baseline. For the T 50 values, the 95% confidence intervals were larger, particularly for the Group C dose group bounded by 93% and 86% reductions in splenic volumes. A clear difference between the groups was evident in E max from the nonoverlapping 95% confidence intervals between the Groups A, B, or C. The rates of reductions stratified after ϳ12 months with greater reductions in Group C.
The dose-response relationships for changes in hepatic volume are presented in Figure 4 , A and B. For Groups A, B, and C, the E max for hepatic volume decreases were 0.61, 0.49, and 0.31, respectively, from baseline corresponding to 39%, 51%, and 69% reductions. Both the dose-dependent effects for E max and T 50 were statistically significant at P Ͻ 0.01. The initial differences for hepatic volume reductions were not as apparent as for the other parameters, but the E max values clearly diverged beyond 60 months. In each dosing group, the total numbers of data points used to generate the curves and values after matching were 1684 for Group A (5 to Ͻ29 U/kg/2 weeks, red), 1845 for Group B (29 to Ͻ48 U/kg/2 weeks, black) and 1409 for Group C (48 to Ͻ75 U/kg/2 weeks, blue). B, Table of calculated values from (A) for maximal effect from baseline (E max ) and time to 50% of maximal effect (T 50 ). The P values are overall for the three dosing groups, and the absence of small overlaps in the 95% confidence intervals indicate the differences between the groups.
As a sensitivity analysis, all models for both unmatched (n ϭ 568) and matched (n ϭ 366) datasets were reproduced using dose categories derived from average dose levels across the initial 1, 2, 3, 4, 5, and 8 years of therapy. These are summarized in 
DISCUSSION
In this study, enzyme therapy dose-response relationships for GD1 were found with alglucerase and/or imiglucerase across the main hematological and visceral manifestations of GD1 within the The E max values were 1.97, 2.01, and 2.10 from baseline for Group A (5 to Ͻ29 U/kg/2 weeks), Group B (29 to Ͻ48 U/kg/2 weeks), and Group C (48 to Ͻ75 U/kg/2 weeks) dosing groups, respectively, corresponding to an approximately 2-fold increase in platelet count by 96 months. In each dosing group, the total number of data points after matching were 1679 for Group A (red), 1850 for Group B (black), and 1411 for Group C (blue). B, Table of calculated values for maximal effect from baseline (E max ) and time to 50% of maximal effect (T 50 ).
The P values and 95% confidence intervals are as in Figure 1B. range of doses typically used in clinical practice. This study was designed to address the question of dose response. In that respect, the outcomes of the study will certainly be of value when considering individual choices for treatment dose. However, in the absence of a validated outcome score and consensus agreement on the appropriate clinical responses, it is not yet possible to provide general clinical guidelines; this also applies to costs. Clearly, future studies will need to address these important, critical issues, but are beyond the scope of this current work (see below). The findings here show that the dose of enzyme therapy affected the level of maximal treatment effect (E max ) across the disease parameters studied (i.e., the higher dose groups achieved a higher maximal level of treatment effect). For most parameters, the T 50 also seemed to be dose dependent.
The results of this study differ from previous studies, which did not identify dose-response relationships for alglucerase or , and Group C (48 to Ͻ75 U/kg/2 weeks) dosing groups, respectively, corresponding to reductions of 68%, 78%, and 90% in splenic volumes. The number of data points in each dosing group after matching was 521 for Group A (red), 482 for Group B (black), and 347 for Group C (blue). B, Table of calculated values from (A) for maximal effect from baseline (E max ) and time to 50% of maximal effect (T 50 ) responses to splenic volume. The P values and 95% confidence intervals are as in Figure 1A .
imiglucerase. [11] [12] [13] [14] [15] 25, 26 These previous studies were limited by small sample sizes, short periods of follow-up, and substantial heterogeneity within and among treatment groups; all of which may have limited the statistical power to identify dose-response relationships. The importance of long-term follow-up is highlighted from the results of this present study. In the first 6 -12 months of follow-up, little distinction between treatment responses for the various dosing groups was seen except for platelets (Figs. 1-4) . However, beyond 12-24 months, the dose-response relationships became more apparent.
The response parameters included in this analysis were those most commonly assessed in previous studies (hemoglobin concentration, platelet count, hepatic and splenic volume) and those that had the most longitudinal data available in the ICGG Gaucher Registry. However, skeletal disease is often the source of significant long-term morbidity. To achieve matched groups , and Group C (48 to Ͻ75 U/kg/2 weeks) dosing groups, respectively, corresponding to reductions of 39%, 51%, and 69% in hepatic volumes. In each dosing group, the numbers of data points after matching were 527 for Group A (red), 472 for Group B (black), and 340 for Group C (blue). B, Table of calculated values from (A) for maximal effect from baseline (E max ) and time to 50% of maximal effect (T 50 ) responses to hepatic volume. The P values and 95% confidence intervals are as in Figure 1 , B.
of adequate size, skeletal parameters were not included in this analysis. However, dose-dependent bone outcomes have been previously reported 27, 28 using alternative methods of analysis, with results consistent with the present study. In a retrospective analysis, 29 a cohort of GD1 patients from Germany (where higher doses of enzyme therapy are typically used) was compared with a cohort from the Netherlands (where lower doses of enzyme therapy are typically used). The two groups were matched for baseline disease severity, and treatment response was compared across several parameters. The group receiving a higher dose of enzyme therapy had a more robust clearance of bone marrow infiltration of Gaucher cells and reductions in the biomarker chitotriosidase, but no dose-dependent differences were detected in effect on liver or spleen enlargement, anemia, or thrombocytopenia. 29 These results were most likely due to the small numbers of matched pairs between the two cohorts for each parameter and the resulting limited statistical power. In another recent analysis of data from the ICGG Gaucher Registry, the effect of imiglucerase on bone mineral density in adults with GD1 was assessed, and statistically significant long-term dose-dependent effects on improvements in bone mineral density were found. 30 On average, the patients who received imiglucerase at 60 U/kg/2 weeks achieved a normal bone mineral density after about 8 years of treatment. 30 Importantly, significant parameter responses for E max or T 50 were obtained for patients in all three dosing groups. In general, dose response was not expected to be reflected in the T 50 values because this is a response parameter for achievement of 50% of E max , rather than the time to a 50% change from the baseline. Although not formally evaluated the 50% change from baseline values are evident from Figures 1-4 . For platelet counts, comparative respective values in Groups A, B, and C are T 50 ϳ 18, 11, and 5 months, and for a 50% increase ϳ50, 28, and 19 months. For splenic volumes, the comparative respective values for Groups A, B, and C are: T 50 ϳ 27, 24, and 54 months and for a 50% decrease ϳ40, 30, and 22 months. Such comparative values cannot be obtained for liver volume because a 50% reduction was not, or barely, achieved in the time frame of the study for the Groups A and B. This cannot be explained by differences in liver volume at baseline, i.e., near normal values before enzyme therapy in one group compared with another, because the propensity score matching directly addressed this confounder. What then might explain the variations in responses at different doses and different times? Although there are no solid explanations, a reasonable assumption would be cognizant that the liver uptake of imiglucerase and alglucerase represents about 75-85% of the dose. 31, 32 Thus, at lower doses, proportionately smaller amounts of administered enzyme would escape this trap, whereas at higher doses more enzyme could circulate to other organs. Greater effects might be anticipated on splenic volume reduction and the derivative effects on platelet counts with higher doses.
For a rare, chronic, heterogeneous disorder such as GD, a large multiarm randomized clinical trial of appropriate size and duration to investigate dose-response relationships may not be possible. However, observational data from an international rare disease registry make such analyses feasible within limits of voluntary observational databases. Application of propensity score matching created conditions similar to a randomized trial and minimized confounding because of differences in baseline severity between groups. Although originally designed for comparison of two groups, propensity scoring has been applied successfully to several defined groups. 33, 34 Nonlinear mixed effects modeling techniques were used to assess treatment responses over a long period of follow-up. 19 -22 However, smaller numbers of patients had assessments reported at the longer term time points, thereby potentially limiting the analyses. In addition, the parameter responses seem to converge, albeit slowly, during later years of follow-up. This methodology enabled analyses of larger, more homogeneous groups of patients with longer follow-up periods than previous studies and may overcome some of the challenges of small sample size, high degree of heterogeneity, and short periods of follow-up found in previous studies. [11] [12] [13] [14] [15] 25, 26, 29 The use of such epidemiologic matching and modeling methods to analyze observational data should have applicability to other rare disease registries.
This study has several potential sources of bias or confounding as with any study using observational data. Patients followed in the ICGG Gaucher Registry are not randomized to drug dose or protocol driven standard dosing, and treated patients are known to have more severe disease than untreated patients. However, the propensity score matching technique was used to minimize such bias in the treatment groups as shown in Table 1 between pre-and postmatching. Additionally, a potential limitation could be introduced by inclusion of less severely involved patients overall, because patients who received lower doses generally had less severe disease. As such, similarly less severe patients who received higher doses might have greater/ more robust responses than those similarly affected patients on lower doses. Although there is no direct way to address this issue in this study, the patients in the final matched groups were representative of the entire patient database of nonsplenectomized GD1 patients (Supplemental Digital Content 1, http://links.lww.com/A694). A more complete answer to this issue will require the use of validated severity indices that show sensitivity/responsiveness to therapy. A potential confounder includes the frequency of administration, which was not examined in this study, although most patients receive infusions every 2 weeks (ICGG Gaucher Registry, data on file).
This study provides strong evidence of incremental doseresponse relationships for enzyme therapy with alglucerase/ imiglucerase within the ranges of doses typically used across several of the main clinical parameters of GD1. This study was designed and executed to determine whether a dose-response exists for selected, clinically relevant disease parameters. The analyses were not specifically directed to address the clinical import of the resultant incremental dose responses. However, the data clearly show significant responses of each parameter within each of the dosing ranges. In addition, the apparent convergence of the response curves for each parameter to a plateau at years 5-8 indicates a potential maximal correction of the initial abnormalties by this time-which might be expected as each parameter normalizes. From such data, one cannot directly conclude that "general maintenance doses" are applicable in the later years of follow-up. There are individual patients in the authors' experiences who require long-term treatment at specific doses to "maintain" improvements in the present disease parameters and in health. Decreasing doses once maximal effects have been achieved should be assessed in the context of the overall health of the individual patient, e.g., there are patients in whom the four parameters assessed here do not seem to correlate with their overall health and quality of life. The development of a "severity index" that includes additional validated assessments of health and well being, including the important biomarkers of disease severity assessed here, may provide a clinical tool to make the responses to such dosage adjustments more objective. Similarly, the judgments of the clinical implications of the incremental dose responses determined here also requires such a standardized consensus agree-ment about the relationship of the present parametric changes and overall disease improvement.
For clinicians managing patients with GD1, these results may provide a basis for dosage selection and adjustment in specific clinical contexts. For example, the more rapid and greater responses in splenic volume decreases and platelet count increases within Group C, provide data to support use of such doses in patients with severe thrombocytopenia, massive splenomegaly, and bleeding. Also, the response characteristics within each dosing group provide benchmarks for treatment of patients who are not responding well to a chosen dose or who are not meeting expected therapeutic goals on a selected dose, 18 because the present results provide overall expectations of responses and the time to achievement of specific improvements in these disease parameters.
Data from the ICGG Gaucher Registry provide evidence of dose-response relationships for enzyme therapy with imiglucerase/alglucerase within the range of doses (about 15-60 U/kg/2 weeks) routinely used in clinical practice across several clinical parameters of GD1. The dose of enzyme therapy seems to affect not only the rate of the treatment effect but also the level of the E max across these parameters. This study also demonstrates that observational data from an international rare disease registry can be analyzed using propensity scoring methods to match groups and nonlinear mixed effects models to assess dose-response relationships.
